In a recent transaction, Norry Elliot, boss Medical (TASE:) Clerk Adaptive immune therapeutics PLC (NASDAQ: ), sold 5,584 American Depositary Shares (ADS) on January 17, 2025. The shares were sold at a weighted average price of $0.5808 per share, generating a total of approximately $3,243. According to InvestingPro analysis, ADAP currently trades below its fair value, with shares down over 50% in the past six months despite maintaining strong liquidity ratios.
Each ADS represents six ordinary shares of the company. The sale was part of the “Sell to Cover” exercise, which was automatically implemented to meet withholding tax liabilities and associated costs. Following this transaction, Elliot retains ownership of 7,510 ADSs. InvestingPro subscribers can access 10 additional key insights about ADAP, including detailed financial health metrics and comprehensive valuation analysis in the Pro Research Report, helping investors make more informed decisions about this volatile biotech stock.
In other recent news, Adaptimmune Therapeutics has garnered significant attention with the FDA granting breakthrough therapy status to its cancer treatment, lete-cel. The designation, intended to accelerate the development and review of potentially significant improvements over existing therapies, is intended for patients with inoperable or metastatic myxoid/round cell liposarcoma who meet specific genetic criteria. In addition, the company plans to initiate an ongoing biologics license application for lete-cel later this year, with a market launch expected in 2026.
As for financial news, analysts at Mizuho (NYSE: ) maintained an outperform rating on Adaptimmune, despite a 50% price target cut. This adjustment was primarily due to changes in the company’s planning and cost reduction plans. The company remains optimistic about the company’s future, in part due to increased revenue projections for Tecelra, Adaptimmune’s lead product candidate, in 2025.
Furthermore, Adaptimmune announced a 33% workforce reduction and a 25% reduction in operating expenses in 2025 as part of a strategy to achieve a break-even financial position by 2027. The company also reported the successful launch of Tecelra and plans to expand authorized treatment centers, expecting modest revenues from the end of 2024, with significant growth expected in 2025. These are among recent developments influencing the company’s cautiously optimistic outlook.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
